Why are Tetratherix (ASX: TTX) shares moving?

Good morning Armchair Army,

Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.

Something is happening with the TTX share price.

After starting last week at around $5, the stock hit $7.50 on Friday and closed the week around $7.

… on no news.

5 consecutive days of buying, 5 consecutive days of the share price moving up: 

Tetratherix (ASX: TTX) has a platform medical device technology with a range of applications: bone healing, tissue spacing, tissue healing…

… and a nasal spray for GLP-1s, hormones and Peptides.

Now, Tetratherix is an incredibly tightly held stock.

The top 20 shareholders own 88%.

This makes it incredibly hard to build a position or buy stock, and anyone doing so could push the share price higher.

(As we’ve seen in the last week).

This also cuts both ways; one big seller can push the price down, too.

But it appears that holders are holding. 

While the buyers enter the frame.

Laws of supply & demand = price goes up.

But why now? 

TTX posted no news last week. 

Ever since TTX announced its nasal spray product for peptides and GLP-1s (such as Ozempic), the narrative has shifted in TTX’s favour.

Right now, the biggest macro thematic in healthcare is peptides.

GLP-1s, Ozempic, BPC-147, Retatrutide.

If you’ve heard of any of these, you’ve either been scrolling TikTok too much OR it's started to become mainstream.

Eli Lilly is sitting on a US$1 trillion market cap and trading at an earnings multiple that better reflects a tech stock rather than a big pharma.

The reason… 

GLP-1 peptides.

In particular, Retatrutide.

Retatrutide is the next generation of weight-loss drugs. 

Phase 3 results posted on Friday indicate 28% weight loss from the highest dosing group:

This puts it in the realm of bariatric surgery (lap band/stomach stapling). 

Just from a needle jab.

Now, I believe retail investors tend to pick stocks based on macro themes first.

They see a trend emerging and want to essentially “bet” on that trend playing out.

In the US, there is no bigger trend in healthcare than peptides and GLP-1s. 

But on the ASX, there is essentially no way to play it.

Look…

I did see Sigma Healthcare talk about how GLP-1 sales have caused a ‘structural uplift’ in Chemist Warehouse revenue.

But if a $33 billion megacap brick-and-mortar company is the only way to play the GLP-1 thematic on the ASX, then that’s slim pickings.

So, as I said, there was no way to play it.

… until TTX.

A few months ago, TTX launched a nasal spray solution for GLP-1s, peptides and hormones, in a deal with Superpower Health.

US$3 million per year…

PLUS a “sell the ingredients” agreement, where TTX will sell product to Superpower Health based on its ability to move units.

The product?

Nasal spray for peptides, GLP-1s and hormones.

It hasn’t launched yet, but it will soon.

Why the nasal spray works so well is that the polymer platform that TTX is built off adheres to the back of the nose and creates a slow release of the peptide into the bloodstream:

Alright, but I thought GLP-1s were owned by Big Pharma… 

How is Superpower Health able to sell this nasal spray with GLP-1s in it?

Superpower Health is a compounding pharmacy.

In the US, it can sell products directly to consumers through the 503A compounding pharmacy exception.

Pharmacies generally cannot compound a drug that is “essentially a copy” of a commercially available product. 

What is defensible, however, is a documented, patient-specific clinical difference that makes the compounded version medically necessary.

A different delivery method can qualify as that clinical difference.

… like a nasal spray.

There is no nasal spray for GLP-1s on the market.

(Nothing even close)

Which means that TTX and Superpower may have one of the only bona fide pathways to sell GLP-1s through the compounding pharmacy exception.

This will sit alongside hormones and peptides… where the Health Secretary RFK Juniro is looking to remove bans on 12 popular peptides:

Peptides are short chains of amino acids and play a crucial role in various biological functions.

GLP-1s are peptides.

(It’s the “P” in GLP)

They are incredibly fragile, which is why most of them are taken through injection. 

But nasal spray delivery could be the solution for better, more effective peptide delivery into the bloodstream.

TTX will be gathering real-world evidence with Superpower to evaluate the nasal spray product's efficacy and tolerability, with the goal of one day bringing its own product to market through the traditional FDA approval route.

But the compounding pharmacy pathway is the fastest way for TTX to get its product into patients' hands.

It is also the key reason I named TTX as my first-ever Armchair Pick at $4.00.

Now, the second reason that I think TTX’s share price is moving is that people want leverage to the catalyst.

TTX has TWO upcoming 510(k) approvals for other applications of its platform technology.

Bone healing for teeth.

Bone healing for orthopedics.

Each of these is a potential catalyst for a re-rate of the stock.

There are a bunch of other smaller catalysts (including data on their other programs) scheduled for this year.

TTX still has a healthy cash balance of $19 million, a good chunk of which is set aside to build out its manufacturing facility and ramp up production.

So, why did TTX’s shares move up last week on no news?

The peptide/GLP-1 story…

Coupled with the catalyst calendar… 

All supported by a tightly held stock.

If you want to read more about the company:

Disclosure: I own 16,250 escrowed TTX shares. TTX has also engaged Armchair Analyst for investor awareness services.

This information is general in nature and does not constitute personal financial advice.

Let’s dive in…

Alcidion (ASX: ALC) signs a 7-year, $35M contract with University Hospitals Sussex to deploy its hospital workflow technology. (ALC)

🪑 While the contract was known to the market, this is still an amazing result. Nice work.

Pacific Edge (ASX: PEB) reports FY26 operating revenue of NZ$11.5M (down 47% YoY) due to the loss of Medicare coverage in April 2025, and a net loss of NZ$35.8M. (PEB)

🪑Poor year reflected in the loss of Medicare coverage. Decent cost control softened the blow, however.

AdAlta Limited (ASX:1AD) engages Dark Horse Consulting to support its FDA IND submission for BZDS1901 CAR-T therapy. (1AD)

NeuroScientific Biopharmaceuticals (ASX: NSB) requests a trading halt pending the release of material results from a Special Access Program. (NSB)

🪑 Already showed a clinical response in 3 of the 4 patients on the Special Access Scheme in Fistulizing Crohn's disease.

Should get the final results now off the back of this.

Jardine Matheson is getting close to an agreement to buy Australia’s biggest medical diagnostics imaging provider, I-MED, for a reported A$3.4 billion. (AFR)

Eli Lilly reports 28.7% weight loss in Retatrutide Phase 3. (Clinical Trials Arena)

This week, a number of ASX-listed companies will present at ASCO, the largest cancer conference on the calendar.

CHM, IMU, TLX, CU6, PER, IMM.

Keep an eye out for any new data presented at the conference.

EMVision Medical Devices (ASX: EMV) secures a $1.2M instalment of a $5M non-dilutive funding package. (EMV)

TruScreen (ASX: TRU) completes a NZ$1.82M capital raise at NZ$0.014. (TRU)

Anteris Technologies (ASX: AVR) establishes an 'at-the-market' equity offering of up to $250M through TD Cowen. (AVR)

🪑 That is a huge ATM facility.

See you all tomorrow,

The Armchair Analyst.

PS. If you’re unhappy with how the proposed 2026-27 Federal Budget could affect the Australian biotech and life sciences industry, there is something that you can do.

AusBiotech is gathering important industry data for its lobbying efforts. 

I’ve filled in the survey; you can too: https://www.surveymonkey.com/r/DKBY758 (5 minutes)